# Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases

> **NCT03606499** · — · COMPLETED · sponsor: **Janssen Cilag S.A.S.** · enrollment: 111 (actual)

## Conditions studied

- Crohn Disease
- Colitis, Ulcerative

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT03606499
- **Lead sponsor:** Janssen Cilag S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-26
- **Primary completion:** 2023-03-17
- **Final completion:** 2023-03-17
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606499, "Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03606499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*